Physician profile
Bridget K Beier
NPI 1538376736
$2,832.35
in general payments reported to CMS, 2019-2025
20 companies · $636 in 2025
The $636 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,655 · 2021: $109 · 2022: $92.74 · 2023: $177 · 2024: $163 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $975.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $1,654.88 | 2019 | |
| Amgen INC. | $230.44 | 2023-2025 | Evenity, Prolia |
| Novo Nordisk INC | $159.36 | 2021-2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $145.37 | 2021-2025 | Freestyle Libre 3 |
| Boston Scientific Corporation | $98.64 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Radius Health, INC. | $92.86 | 2025 | Tymlos |
| Medtronic, INC. | $69.49 | 2023-2024 | Inpen Smart Insulin Delivery System |
| Tandem Diabetes Care, INC. | $53.14 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $40.89 | 2023-2025 | |
| Lilly USA, LLC | $35.59 | 2023-2024 | Jardiance |
| Dexcom, INC. | $34.56 | 2024-2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $33.83 | 2025 | |
| Abbvie INC. | $30.72 | 2025 | |
| Sequel Med Tech, LLC | $29.97 | 2025 | Twiist |
| Madrigal Pharmaceuticals | $28.06 | 2025 | Rezdiffra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $24.09 | 2023 | Tepezza |
| Antares Pharma, INC. | $22.39 | 2025 | Xyosted |
| Insulet Corporation | $18.26 | 2022 | |
| Ascendis Pharma Endocrinology INC | $17.48 | 2024 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Beier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.